| Aumolertinib studied in …STUDIED_INderived44 of 44show fewer |
|---|
| → studied in | NCT07183189Phase 3 · active not recruiting A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07699952Phase 2 · not yet recruiting First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04841811Phase 3 · active not recruiting MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06474455Phase 1/Phase 2 · recruiting A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors · 44 trials list this drug (19 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06300424Phase 2 · active not recruiting Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07130916Phase 1 · recruiting A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06417008Phase 2/Phase 3 · recruiting A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06951464Phase 2 · recruiting A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06947811Phase 1/Phase 2 · recruiting A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations · 44 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 44 trials list this drug (19 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06752408Phase 2 · not yet recruiting Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06227897Phase 2 · withdrawn Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923906Phase 3 · active not recruiting Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04687241Phase 3 · active not recruiting Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463171Phase 2 · unknown Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04808752Phase 2 · unknown Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05946460Phase 2 · unknown Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04354961Phase 2 · unknown Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma · 44 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043973Phase 3 · recruiting Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05994339Phase 2/Phase 3 · unknown Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05826483Phase 1 · unknown Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04922138Phase 2 · unknown Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05800223Phase 3 · recruiting Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04519983Phase 2 · unknown Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05768490Phase 3 · recruiting Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases · 44 trials list this drug (19 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02981108Phase 1/Phase 2 · unknown A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03849768Phase 3 · unknown A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05662813Phase 2 · unknown Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05503888Phase 1/Phase 2 · not yet recruiting Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04951635Phase 3 · recruiting A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762459Phase 3 · enrolling by invitation Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04778800NA · unknown A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04951648Phase 3 · unknown A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04952168Phase 2 · unknown Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04944069NA · unknown Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04905550Phase 2 · unknown Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04882345Phase 2 · unknown Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment · 44 trials list this drug (19 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04636593Phase 2 · unknown A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643847Phase 2 · unknown A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases · 44 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04592666Phase 2 · unknown Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04553887Phase 2 · unknown Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04500704Phase 3 · unknown Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04500717Phase 3 · unknown Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04455594Phase 2 · unknown Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC · 44 trials list this drug (19 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |